<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445248</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019C2201</org_study_id>
    <secondary_id>2014-003060-20</secondary_id>
    <nct_id>NCT02445248</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients</brief_title>
  <acronym>JULIET</acronym>
  <official_title>A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in&#xD;
      adult patients with relapsed or refractory DLBCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <completion_date type="Anticipated">February 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo cellular Pharmacokinetic (PK) profile of CTL019 transduced cells into target tissues</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immunogenicity to CTL019</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with presence of exposure to replication-competent lentivirus (RCL) as Assessed by quantitative polymerase chain reaction (qPCR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of immunogenicity to CTL019</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>CTL019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTL019</intervention_name>
    <description>Single arm</description>
    <arm_group_label>CTL019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any screening procedures&#xD;
&#xD;
          -  Histologically confirmed DLBCL at last relapse(by central pathology review before&#xD;
             enrolment.&#xD;
&#xD;
             .- Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab&#xD;
             and anthracycline and either having failed autologous Hematopoietic stem cell&#xD;
             transplantation (ASCT), or being ineligible for or not consenting to ASCT&#xD;
&#xD;
          -  Measurable disease at time of enrollment&#xD;
&#xD;
          -  Life expectancy ≥12 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at&#xD;
             screening&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
               -  Renal function defined as:&#xD;
&#xD;
                    -  A serum creatinine of ≤1.5 x Upper Limit of Normal ULN OR&#xD;
&#xD;
                    -  Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73 m2&#xD;
&#xD;
               -  Liver function defined as:&#xD;
&#xD;
                    -  Alanine Aminotransferase (ALT) ≤ 5 times the Upper Limit of Normal (ULN) for&#xD;
                       age&#xD;
&#xD;
                    -  Bilirubin ≤ 2.0 mg/dl with the exception of patients with&#xD;
                       Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome&#xD;
                       may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin&#xD;
                       ≤ 1.5 x ULN&#xD;
&#xD;
               -  Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and&#xD;
                  pulse oxygenation &gt; 91% on room air&#xD;
&#xD;
               -  Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ≥ 45%&#xD;
                  confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)&#xD;
&#xD;
               -  Adequate bone marrow reserve without transfusions defined as:&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) &gt; 1.000/mm3&#xD;
&#xD;
                    -  Absolute lymphocyte count (ALC) ≥ 300/mm3&#xD;
&#xD;
                    -  Platelets ≥ 50.000//mm3&#xD;
&#xD;
                    -  Hemoglobin &gt; 8.0 g/dl&#xD;
&#xD;
               -  Must have an apheresis product of non-mobilized cells accepted for manufacturing&#xD;
&#xD;
               -  Women of child-bearing potential (defined as all women physiologically capable of&#xD;
                  becoming pregnant) and all male participants must agree to use highly effective&#xD;
                  methods of contraception for at least 12 months following CTL019 infusion and&#xD;
                  until CAR T cells are no longer present by PCR on two consecutive tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19&#xD;
             therapy&#xD;
&#xD;
          -  Treatment with any prior gene therapy product&#xD;
&#xD;
          -  Active Central Nervous System (CNS) involvement by malignancy&#xD;
&#xD;
          -  Prior allogeneic HSCT&#xD;
&#xD;
          -  Eligible for and consenting to ASCT&#xD;
&#xD;
          -  Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of infusion&#xD;
&#xD;
          -  Investigational medicinal product within the last 30 days prior to screening&#xD;
&#xD;
          -  The following medications are excluded:&#xD;
&#xD;
               -  Steroids: Therapeutic doses of steroids must be stopped &gt; 72 hours prior to&#xD;
                  CTL019 infusion. However, the following physiological replacement doses of&#xD;
                  steroids are allowed: &lt; 6 - 12 mg/m2/day hydrocortisone or equivalent&#xD;
&#xD;
               -  Immunosuppression: Any immunosuppressive medication must be stopped ≥ 4 weeks&#xD;
                  prior to enrollment&#xD;
&#xD;
               -  Antiproliferative therapies other than lymphodepleting chemotherapy within two&#xD;
                  weeks of infusion&#xD;
&#xD;
               -  Antibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5&#xD;
                  half-lives of the respected antibody, whichever is longer&#xD;
&#xD;
               -  CNS disease prophylaxis must be stopped &gt; 1 week prior to CTL019 infusion (e.g.&#xD;
                  intrathecal methotrexate)&#xD;
&#xD;
          -  Prior radiation therapy within 2 weeks of infusion&#xD;
&#xD;
          -  Active replication of or prior infection with hepatitis B or active hepatitis C( HCV&#xD;
             RNA positive )&#xD;
&#xD;
          -  HIV positive patients&#xD;
&#xD;
          -  Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood&#xD;
             culture positive ≤ 72 hours prior to infusion)&#xD;
&#xD;
          -  Unstable angina and/or myocardial infarction within 6 months prior to screening&#xD;
&#xD;
          -  Previous or concurrent malignancy with the following exceptions:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell carcinoma (adequate wound healing&#xD;
                  is required prior to study entry)&#xD;
&#xD;
               -  In situ carcinoma of the cervix or breast, treated curatively and without&#xD;
                  evidence of recurrence for at least 3 years prior to the study&#xD;
&#xD;
               -  A primary malignancy which has been completely resected and in complete remission&#xD;
                  for ≥ 5 years&#xD;
&#xD;
          -  Investigational medicinal product within the last 30 days prior to screening&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Intolerance to the excipients of the CTL019 cell product&#xD;
&#xD;
          -  Cardiac arrhythmia not controlled with medical management&#xD;
&#xD;
          -  Patients on oral anticoagulation therapy&#xD;
&#xD;
          -  Prior treatment with any adoptive T cell therapy&#xD;
&#xD;
          -  Patients with active neurological auto immune or inflammatory disorders(e.g. Guillain&#xD;
             Barre Syndrome, Amyptrophic Lateral Sclerosis)&#xD;
&#xD;
        Other protocol-related inclusion/exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona Mayo Clinic Building</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco SC-4</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center, Hematology &amp; Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Cancer Center at Johns Hopkins Hospital SC-2</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota SC C2201</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Unversity Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University James Cancer Hospital &amp;</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center SC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <zip>VIC 2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <zip>VIC 3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido</state>
        <zip>060 8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse large B-cell lymphoma,</keyword>
  <keyword>DLBCL,</keyword>
  <keyword>Relapsed/refractory,</keyword>
  <keyword>CTL019</keyword>
  <keyword>CART19</keyword>
  <keyword>CART</keyword>
  <keyword>CAR T cells</keyword>
  <keyword>Chimeric antigen receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

